In the AICE study, all CBD patients registered at the HCs at the COVID-19 outbreak are eligible and will be asked to be enrolled, irrespective of age and CBD severity, at routine visits or by telematic communications. Keywords: congenital bleeding disorders; COVID-19; epidemiology; haemophilia; observational study; SARS-CoV-2 EN congenital bleeding disorders COVID-19 epidemiology haemophilia observational study SARS-CoV-2 e575 e578 4 07/21/21 20210701 NES 210701 Since January 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is challenging healthcare systems worldwide with the impact of the associated disease (COVID-19), often characterized by severe interstitial pneumonia and respiratory insufficiency, up to need for intensive care (IC) and fatal outcome, particularly in elderly individuals and those with multi-morbidities. Patients with congenital bleeding disorders appear to be less severely affected by SARS-CoV-2: is inherited hypocoagulability overcoming acquired hypercoagulability of coronavirus disease 2019 (COVID-19)?. [Extracted from the article]